The future of the global clinical trial imaging market looks promising with opportunities in the pharmaceutical company, biotechnology company, medical device manufacturer, contract research organization, academic and government research institute markets. The global clinical trial imaging market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.6% from 2024 to 2030. The major drivers for this market are increasing number of CROs, significantly growing pharmaceutical and biotechnology industries, and increasing R&D spending to discover drugs and therapies.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the clinical trial imaging
market by product & services (software and services), modality (computed
tomography, magnetic resonance imaging, ultrasound, positron emission
tomography, X-ray, and echocardiography), therapeutic area (oncology,
infectious diseases, neurology, CVS, endocrinology, and immunological
disorder), end use (pharmaceutical companies, biotechnology companies, medical
device manufacturer, contract research organizations, academic and government
research institutes, and others),and region (North America, Europe, Asia
Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market, computed
tomography, magnetic resonance imaging, ultrasound, positron emission
tomography, x-ray, and echocardiography are the major segments of clinical
trial imaging market by modality. Lucintel forecasts that computed tomography
will remain the largest segment over the forecast period due to including the
increasing presence of contract research organizations (CROs) and rising
research and development investments.
Within this market, pharmaceutical
companies will remain the largest segment due to increasing demand for new
treatments and medications aimed at addressing chronic diseases.
North America will
remain the largest region over the forecast period due to the presence of large
outsourcing companies and rising R&D activities in the region.
ICON, Biotelemetry,
Medpace Holdings, Biomedical Systems Corporation, Bioclinica, IXICO, Resonance
Health, Radiant Sage, Intrinsic Imaging, and Cardiovascular Imaging
Technologies are the major suppliers in the clinical trial imaging market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment